Fundz

Who to call at LENZ Therapeutics, Inc., and when

Fundz watches for the moments LENZ Therapeutics, Inc. starts buying, and tells you who to reach.

  • An alert the day LENZ Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at LENZ Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at LENZ Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KHIGH RiskNegative

LENZ Therapeutics, Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

graphitebio.com
Filed: Oct 28, 2026San Francisco, CaliforniaCIK: 0001815776Biotechnology
View on SEC.gov

The seat is still open. No replacement has been named 25 days after this filing.

See every company with multiple executive changes →

Executive Summary

Analysis of 8-K filing content

LENZ Therapeutics' President and CEO Evert Schimmelpennink resigned effective December 1, 2026, with CFO Daniel Chevallard assuming interim leadership. Concurrently, the company approved a major strategic reorganization reducing headcount by 75% to approximately 40 employees, with estimated non-recurring charges of $5 million primarily for severance, signaling significant operational restructuring and financial pressure.

Other companies that filed an 8-K Item 5.02 (Executive Change) the same week

Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.

  • Compass Minerals International, Inc. (October 28, 2026): Compass Minerals appointed Brett Teuscher as Chief Accounting Officer on October 28, 2026, following Ashley Ward's resignation on October 23, 2026.
  • Radian Group Inc. (October 28, 2026): Radian Group Inc. appointed Daniel Kobell as Senior Executive Vice President and Chief Financial Officer on October 28, 2026, after he served as Interim CFO since February 2026.
  • Gain Therapeutics, Inc. (October 28, 2026): Gain Therapeutics appointed Jeanette Weidner as Vice President of Finance effective October 28, 2026, with responsibility for principal financial and accounting officer duties.
  • Monroe Federal Bancorp, Inc. (October 28, 2026): Monroe Federal Bancorp appointed Charles G. Brown III as President and CEO effective October 26, 2026, succeeding Lewis R. Renollet who transitioned to Senior Executive Vice...
  • Techlott Inc. (October 28, 2026): Eldar Grady, Chairman and Executive Chairman of Techlott Inc., resigned from all positions effective October 28, 2026, under a separation agreement that terminates his consulting...
  • ABM Industries Incorporated (October 28, 2026): Rene Jacobsen, Executive Vice President and Chief Operating Officer of ABM Industries, announced his voluntary retirement effective February 1, 2027, with a transition to...

Key Takeaways

CEO departure effective December 1, 2026, with CFO Daniel Chevallard transitioning to Interim President and CEO role

Strategic reorganization approved reducing headcount by approximately 75% to ~40 full-time employees, focused on consumer marketing and cost reduction

3 more takeaways

Filing Overview

Form Type8-K
Filing DateOct 28, 2026
Item5.02
CategoryExecutive Change
CIK0001815776
Accession #0001815776-26-000056
Risk LevelHIGH
SentimentNegative
Signalneutral
Topics
executive departureleadership transitionrestructuring

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

LENZ Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.